Anesthetics isoflurane and sevoflurane attenuate flagellin-mediated inflammation in the lung.
Anesthetics, Inhalation
/ chemistry
Animals
Cell Line, Tumor
Cystic Fibrosis
/ complications
Epithelial Cells
/ drug effects
Female
Flagellin
/ chemistry
Humans
Inflammation
/ metabolism
Inflammation Mediators
/ metabolism
Interleukin-8
/ metabolism
Isoflurane
/ chemistry
Lung
/ drug effects
Male
Mice
Molecular Docking Simulation
NF-kappa B
/ metabolism
Neutrophils
/ drug effects
Pseudomonas Infections
/ complications
Pseudomonas aeruginosa
/ immunology
Retrospective Studies
Sevoflurane
/ chemistry
Toll-Like Receptor 5
/ chemistry
Cystic fibrosis
Flagellin
Toll-like receptor 5
Volatile anesthetics
Journal
Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516
Informations de publication
Date de publication:
11 06 2021
11 06 2021
Historique:
received:
12
04
2021
accepted:
13
04
2021
pubmed:
25
4
2021
medline:
10
8
2021
entrez:
24
4
2021
Statut:
ppublish
Résumé
Isoflurane and sevoflurane are volatile anesthetics (VA) widely used in clinical practice to provide general anesthesia. We and others have previously shown that VAs have immunomodulatory effects and may have a significant impact on the progression of disease states. Flagellin is a component of Gram negative bacteria and plays a significant role in the pathophysiology of bacterial pneumonia through its binding to Toll-like Receptor 5 (TLR5). Our results showed that VAs, not an intravenous anesthetic, significantly attenuated the activation of TLR5 and the release of the neutrophil chemoattractant IL-8 from lung epithelial cells. Furthermore, flagellin-induced lung injury was significantly attenuated by VAs by inhibiting neutrophil migration to the bronchoalveolar space. The lungs of cystic fibrosis (CF) patients are highly colonized by Pseudomonas aeruginosa, which causes inflammation. The retrospective study of oxygenation in patients with CF who had received VA versus intravenous anesthesia suggested that VAs might have the protective effect for gas exchange. To understand the interaction between VAs and TLR5, a docking simulation was performed, which indicated that isoflurane and sevoflurane docked into the binding interphase between TLR5 and flagellin.
Identifiants
pubmed: 33894411
pii: S0006-291X(21)00650-1
doi: 10.1016/j.bbrc.2021.04.045
pmc: PMC8113123
mid: NIHMS1696759
pii:
doi:
Substances chimiques
Anesthetics, Inhalation
0
Inflammation Mediators
0
Interleukin-8
0
NF-kappa B
0
TLR5 protein, human
0
Toll-Like Receptor 5
0
Flagellin
12777-81-0
Sevoflurane
38LVP0K73A
Isoflurane
CYS9AKD70P
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
254-260Subventions
Organisme : NIAID NIH HHS
ID : R21 AI158886
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Toxicol Sci. 2017 Apr 1;156(2):402-411
pubmed: 28003439
Infect Immun. 2005 Dec;73(12):8237-46
pubmed: 16299320
J Anesth. 2015 Aug;29(4):570-9
pubmed: 25716536
J Inflamm (Lond). 2005 Nov 29;2:16
pubmed: 16316467
Blood. 2003 Oct 1;102(7):2660-9
pubmed: 12829592
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
Trends Microbiol. 2004 Nov;12(11):509-17
pubmed: 15488392
Anesth Analg. 2011 Apr;112(4):830-8
pubmed: 21385989
Am J Physiol Cell Physiol. 2006 Mar;290(3):C678-90
pubmed: 16251478
Cell Mol Immunol. 2017 Dec;14(12):1017-1019
pubmed: 29151579
PLoS One. 2019 May 9;14(5):e0216163
pubmed: 31071106
Am J Respir Crit Care Med. 2017 Mar 15;195(6):792-800
pubmed: 27611637
Anesth Analg. 2020 Aug;131(2):631-639
pubmed: 32149756
Curr Top Microbiol Immunol. 2002;270:81-92
pubmed: 12467245
FASEB J. 2019 Dec;33(12):14528-14541
pubmed: 31675483
BMC Pulm Med. 2014 Jun 09;14:100
pubmed: 24909229
J Anesth. 2013 Apr;27(2):261-8
pubmed: 23096126
Exp Mol Med. 2017 Sep 1;49(9):e373
pubmed: 28860663
FASEB J. 2012 Nov;26(11):4408-17
pubmed: 22815384
J Biol Chem. 2000 Sep 22;275(38):29731-6
pubmed: 10882713
Toxicol Lett. 2017 Jan 15;266:23-31
pubmed: 27940100
J Immunol. 2004 Apr 15;172(8):5056-62
pubmed: 15067088
Surgery. 2005 Oct;138(4):560-71; discussion 571-2
pubmed: 16269283
Nucleic Acids Res. 2011 Jul;39(Web Server issue):W270-7
pubmed: 21624888
PLoS One. 2013;8(4):e60415
pubmed: 23573252
Nature. 2001 Apr 26;410(6832):1099-103
pubmed: 11323673
Am J Physiol Lung Cell Mol Physiol. 2004 Aug;287(2):L428-37
pubmed: 15121639
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12487-92
pubmed: 16891416
Science. 2012 Feb 17;335(6070):859-64
pubmed: 22344444
Crit Care Med. 2012 Aug;40(8):2320-6
pubmed: 22622405
J Immunol. 2008 Jun 1;180(11):7764-73
pubmed: 18490781